Stem Cell Proposal (Animation) "E. Pluribus UNUM" By Jef.Thornton and Steven Bellettini This is an animation project me and My classmate steve did for a class assignment. It is in support of the michigan stem cell research proposal. enjoy :^) By: jeffypoo8 … Continue reading →

Young Turks YT@11 Episode 18 Part 1 - RMS Regrow RMS Regrow: Making stem cell regeneration accessible to all Stem cell research and treatment have been gaining ground over the last few years. The idea behind stem cell research and treatments is a type of intervention which introduces new adult stem cells into damaged tissue to treat disease or an injury. Many medical researchers believe that stem cell treatments have the potential to be a game changer in the world of medicine. This treatment is particularly relevant to India and can help Indians diagnosed with blood cancer and children with Thalassemia. According to the Indian Stem Cell Transplant Registry the number of blood stem cell transplants done in India till 2011 stands at a measly 4015. This means it is imperative to move towards making blood stem cell treatments more cost effective and affordable to more patients. Contributing to this cause is 26 year old Satyen Sanghavi whose venture Regenerative Medical Services makes both stem cell banking and bone and cartilage regeneration accessible to Indians. Sanghavi has done his Masters in Stem Cell Technology from UK. The 26 year old who loves traveling, sports and reading is helping patients regrow. … Continue reading →

President Obama, lifting an eight-year limit on federal funding of stem cell research, today portrayed his decision as part of a broader move to focus on science instead of politics. Besides signing an executive order (read it here) reversing the Bush administration restrictions, Obama is also issuing a presidential memorandum (read it here) directing the head of the White House Office of Science and Technology Policy to develop a strategy for restoring scientific integrity to government decision making. The goal, the president said: "To ensure that in this new administration, we base our public policies on the soundest science; that we appoint scientific advisers based on their credentials and experience, not their politics or ideology; and that we are open and honest with the American people about the science behind our decisions." On embryonic stem cell research in particular, Obama acknowledged the religious-based opposition. But he said there is an ethical way to do such research. "Rather than furthering discovery, our government has forced what I believe is a false choice between sound science and moral values," he said in the East Room of the White House, filled with advocates of stem cell research who cheered and applauded his annoucement. … Continue reading →

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that cardiologist Stephen E. Epstein, MD, Director of Translational Research of the MedStar Heart Institute, Washington Hospital Center, has accepted the position of Chairman of Stemedicas Scientific and Medical Advisory Board for the Companys Cardiology Division. Dr. Epstein served for over 30 years as Chief of the Cardiology Branch of the National Heart, Lung and Blood Institute (NHLBI) in Bethesda, Maryland. San Diego, CA (PRWEB) March 04, 2013 With more than 500 publications in peer-reviewed medical journals, Dr. Epstein is a recognized international authority on angiogenesis and the role of infection in atherosclerosis. He and his colleagues recently developed stem cell strategies for enhancing collateral development (new blood vessel growth) and are currently focused on understanding and treating cardiovascular disease at the molecular level by identifying the molecular mechanisms responsible for development of vulnerable plaques. These efforts have included examining possible genetic polymorphisms and of circulating biomarkers as indicators that a given patient is at risk of plaque rupture. Dr. Epstein has also explored how aging leads to collateral dysfunction and the related molecular mechanisms. One of Dr. Epsteins current primary areas of … Continue reading →

CARLSBAD, Calif., March 4, 2013 /PRNewswire/ --Life Technologies Corporation (LIFE) announced today that it has signed a collaborative research agreement and related license with Harvard University under which it has acquired exclusive rights to develop a panel of characterization assays designed to rapidly evaluate human pluripotent stem (hPS) cells for their utility in a variety of discovery and translational research applications. The license expands Life's growing portfolio of stem cell research products and deepens its commitment to customers in the field. The panel, which will be offered on the company's market-leading semiconductor sequencing and PCR-based genetic analysis platforms, will help overcome major hurdles that impede stem cell technology from moving into the clinic. Current methods for evaluating pluripotency the potential for induced pluripotent stem (iPS) cells to differentiate into any cell type are laborious, costly and can produce ambiguous results. Standardizing the way researchers characterize iPS cells will allow them to quickly identify the most promising cell lines and avoid wasting time and resources on cells that do not possesses the appropriate characteristics. Such efficiency could accelerate applications ranging from development of "disease-in-a-dish" models from patient-derived cells and drug screening, to the eventual use of pluripotent cells as a renewable … Continue reading →